HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Fibrinolytic Defect

Networked: 7 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Disease Context: Research Results

Hemic and Lymphatic Diseases: 6
- Hematologic Diseases: 3366
  - Blood Coagulation Disorders: 167
    - Fibrinolytic Defect: 7

Related Diseases

1.	Quebec platelet disorder
2.	Insulin Resistance
3.	Hypertension (High Blood Pressure)

Experts

1.	Hayward, Catherine P M: 1 article (12/2020)
2.	Rivard, Georges E: 1 article (12/2020)
3.	Tasneem, Subia: 1 article (12/2020)
4.	Görög, Anna: 1 article (10/2016)
5.	Kolev, Krasimir: 1 article (10/2016)
6.	Kárpáti, Sarolta: 1 article (10/2016)
7.	Mayer, Balázs: 1 article (10/2016)
8.	Németh, Krisztián: 1 article (10/2016)
9.	Silló, Pálma: 1 article (10/2016)
10.	Szabó, László: 1 article (10/2016)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Fibrinolytic Defect:

1.	Dapsone FDA Link 10/01/2016 - "This study revealed that the fibrinolytic potential was impaired in the plasma of untreated DH patients, whereas dapsone corrected the fibrinolytic defect. "
2.	Plasminogen Activator Inhibitor 1IBA 04/01/2003 - "Locally increased amplification of plasminogen activator inhibitor-1 (PAI-1) is largely responsible for this fibrinolytic defect. " 05/01/1996 - "Thus, patients with hypertension have impaired fibrinolytic activity due to increased PAI-1 when compared to normotensive controls, and the magnitude of this fibrinolytic defect is greater in hypertensive patients who have insulin resistance. " 07/01/2004 - "Despite any preconceptions, examination for a fibrinolytic defect ultimately demonstrated a PAI-1 antigen level of 11.4 ng/mL (4.0-43 ng/mL) and PAI-1 activity less than 5 AU/mL (5-37 AU/mL) and clinically supported a diagnosis of a hereditary, qualitative PAI-1 defect. "
3.	Factor XIIa (Coagulation Factor XIIa)IBA 02/01/1974 - "Addition of intact activated Hageman factor corrected the coagulation, fibrinolytic, and chemotactic defects and addition of Hageman factor fragments corrected the fibrinolytic defect and partially corrected the chemotactic defect; neither of these corrected the kinin-generating defect. "
4.	Plasminogen Activators (Plasminogen Activator)IBA 09/01/1991 - "This fibrinolytic defect appeared attributable to disproportionate increases in circulating plasminogen activator inhibitor-1 levels. "
5.	KininsIBA 02/01/1974 - "Addition of intact activated Hageman factor corrected the coagulation, fibrinolytic, and chemotactic defects and addition of Hageman factor fragments corrected the fibrinolytic defect and partially corrected the chemotactic defect; neither of these corrected the kinin-generating defect. "
6.	Factor XII (Hageman Factor)IBA 02/01/1974 - "Addition of intact activated Hageman factor corrected the coagulation, fibrinolytic, and chemotactic defects and addition of Hageman factor fragments corrected the fibrinolytic defect and partially corrected the chemotactic defect; neither of these corrected the kinin-generating defect. "
7.	AntigensIBA 07/01/2004 - "Despite any preconceptions, examination for a fibrinolytic defect ultimately demonstrated a PAI-1 antigen level of 11.4 ng/mL (4.0-43 ng/mL) and PAI-1 activity less than 5 AU/mL (5-37 AU/mL) and clinically supported a diagnosis of a hereditary, qualitative PAI-1 defect. "

Therapies and Procedures

1.	Therapeutics 12/01/2020 - "Improved platelet counts during prolonged tranexamic therapy for Quebec platelet disorder implicate the underlying fibrinolytic defect as the cause of lower platelet counts."